REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease
Objective: To present the REGENERATE-PD study design: a phase 2, randomized, double-blind, surgery-controlled trial assessing efficacy and safety of intraputaminal adeno-associated virus serotype 2 containing…Preliminary Efficacy of Bilateral Intraputaminal Delivery of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson’s Disease: 18-Month Follow-Up From a Phase 1b Study
Objective: To assess the preliminary efficacy of bilateral intraputaminal delivery of adeno-associated virus serotype 2 containing glial cell line–derived neurotrophic factor (AAV2-GDNF; AB-1005) for patients…Glial neurotrophiz factor as a differential marker of Parkinson`s disease and vascular parkinsonism
Objective: To analysis of glial neurotrophic factor content in blood serum of patients with PD and VP. Background: Parkinson's disease (PD) and vascular parkinsonism (VP)…The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
Objective: To investigate whether NLX-112, a potent and selective 5-HT1A agonist is neuroprotective in a mouse MPTP model of Parkinson’s Disease (PD) [1]. Background: There…Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?
Objective: To determine if GDNF receptor expression levels in the striatum or substantia nigra (SN) change in relation to differences in tyrosine hydroxylase (TH) and…Dopamine neuron platform for screening molecular mechanisms and inhibitory drugs against alpha-synuclein aggregation
Objective: Optimization of a dopamine neuron based,in vitro platform is beneficial for studying molecular mechanisms of alpha-synuclein aggregation,and screening of inhibitory drugs and deducing their…GDNF Gene Therapy for Parkinson’s Disease (PD): Preliminary Safety and Clinical Findings from a Phase Ib Study
Objective: Assess the safety and tolerability of intraputaminal AAV2-GDNF in mild to moderate PD Background: Glial cell line-derived neurotrophic factor (GDNF) is critical for dopaminergic…Type-3 Metabotropic Glutamate Receptors and Parkinson’s Disease: Preclinical Studies and Human Genetics
Objective: In a MPTP mice model of toxicological parkinsonism we examine whether the presence or absence of mGlu3 receptors is neuroprotective. We also evaluted association…Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease
Objective: Our goal is to develop small molecules which support and restore nigrostriatal dopamine neurons by activation of glial cell line-derived-neurotrophic factor (GDNF) receptors. Background:…Bilateral Putaminal AAV2-GDNF Delivery the Treatment of Advanced Parkinson’s Disease
Objective: To investigate the safety, tolerability, and early clinical efficacy of escalating doses of AAV2-GDNF delivered into the bilateral putamen of patients with advanced PD…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.